Navigation Links
Immtech Reports Fiscal Second Quarter 2008 Results
Date:11/8/2007

NEW YORK, Nov. 8 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) today announced results for its fiscal second quarter ended September 30, 2007.

For the three months ended September 30, 2007, revenues were $1,030,000, as compared to $491,000 for the three months ended September 30, 2006. The increase was primarily attributable to revenues relating to a licensing agreement and research agreement. Loss from operations for the three months ended September 30, 2007 was $3,466,000, as compared to a loss from operations of $1,753,000 for the three months ended June 30, 2006. The three month period ended September 30, 2006 included a receivable of $1,874,000 relating to the Neurochem litigation award. Net loss attributable to common stockholders for the three months ended September 30, 2007 was $3,469,000, or $0.23 per share, compared to a loss of $1,758,000, or $0.13 per share, in the previous year.

At September 30, 2007, unrestricted cash and cash equivalents were $9,840,000 as compared to $12,462,000 at March 31, 2007. For the same periods, restricted funds on deposit were $694,000 and $3,119,000, respectively. Subsequent to September 30, 2007, a payment of $5,123,000 was received to further the development of pafuramidine, the Company's oral drug candidate, in the Phase III African sleeping sickness trial.

During the three-month period ended September 30, 2007, several significant milestones were achieved. In addition to the Par Pharmaceutical agreement, Immtech received orphan drug status from the USFDA for pafuramidine to treat malaria and African sleeping sickness, added a new board member and a strategic advisor to the team, and received from China's State Food and Drug Administra
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Chinese SFDA Grants Immtech Fast Track Status
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
6. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Spherix Reports Second Quarter Earnings
9. Tapestry Reports Second Quarter 2007 Results
10. Callisto Reports on Second-Quarter 2007 Milestones
11. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Sorrento Therapeutics, Inc. ... Fast-Track Advanced Technology Small Business Technology Transfer Research ... Allergy and Infectious Diseases (NIAID), a division of ... development of novel human antibody therapeutics to combat ... or Staph) infections, including methicillin-resistant S. aureus ...
(Date:5/17/2013)... SAN DIEGO and CAMBRIDGE, Mass., May 17, 2013 ... announce that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: ... District Court for the District of Massachusetts ... of its officers violated the Securities Exchange Act of ... May 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- United Medical Education, a company that ... Pediatric Advanced Life Support (PALS) and Basic Life Support ... ACLS online course manuals. In order to gain ... build an account with the company. By offering the ... Medical Education is setting a precedent among similar companies. ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2
... WIRE)--Apr 13, 2007 - Ascenta Therapeutics,Inc. announced today ... be featured in three oral,presentations and several poster ... American Association for Cancer Research,(AACR), to be held ... MDM2 program has been selected for presentation at ...
... /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. , a global, pure ... today announced that it,will present two abstracts outlining ... well as in vivo data on its GHRH ... for the treatment of cancer. These abstracts will ...
Cached Medicine Technology:Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 2Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 3Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 4Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 5Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 6AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 2AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 3
(Date:5/19/2013)... (PRWEB) May 19, 2013 According to a ... Firmers” many people are self-conscious about the appearance of certain ... option when diet and exercise fail to tone and tighten ... appeal to those looking to get the firmest body ... an effective mini-overview,” says Dr. Simon Ourian, Medical Director of ...
(Date:5/19/2013)... People in Minnesota have a great option to ... its 28 Day Fat Loss Formula. The best part ... their own home. The product sells for $135 dollars and ... accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is almost ... but after using the 28 Day Fat Loss Formula they ...
(Date:5/19/2013)... May 19, 2013 The muscles in ... their functionality and one of the biggest and most ... nervous system. The peripheral system comprises of peripheral nerves ... cord. These nerves ensure that the limbs and hands, ... when these nerves get damaged due to trauma or ...
(Date:5/19/2013)... According to a new market ... (2013 – 2018): By Applications (Healthcare (Endoscopy, Radiology, ... CMOS, Contact IS, Infrared, X-Ray) And Geography" published ... was $8.00 billion in 2012 and is expected ... estimated CAGR of 3.84% from 2013 to 2018. ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 The report ... Global Trends & Forecasts up to 2017” published by ... market with analysis and forecasting of the global volume ... identifies the driving and restraining factors for the global ... imperatives, and challenges. The market is segmented and revenue ...
Breaking Medicine News(10 mins):Health News:Body Firming – The Hottest Treatments Available 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3
... Structured as a Social Business Enterprise, Facility Can ... Cataract Operations Annually, DHAKA, Bangladesh, May 2 ... to perform 50,000 eye examinations and,10,000 cataract operations ... laureate Professor Muhammad Yunus and the Hon,ble Adviser, ...
... New York, NYHealth insurance coverage and unpaid health care ... coverage costs the U.S. public $45 billion a year, ... today. This includes $33 billion in the cost of ... Health Insurance Program, and $12 billion in uncompensated care ...
... Approval Ratings Consistent with Public,s Support of ,Medicare for ... All, or Single-payer Healthcare, ... enact healthcare reform surfacing in Sacramento, a new field poll,this week ... of the California Nurses Association and registered,nurses., A poll this ...
... -- Beginning this Mother,s,Day, women across America will ... shows that when women take care of themselves, ... of this nationwide,initiative and to celebrate the launch ... the five minute daily solution for your smile ...
... PET Registry (NOPR) Study Showcases the Need to,Expand ... Cancer Treatment, WASHINGTON, May 1 US ... treatment and research networks,representing approximately 1,200 oncologists nationwide, ... Clinical Oncology (JCO) that,demonstrates the value of positron ...
... is available in French . , , ... Health Centre (MUHC) have performed the worlds first ... the new system developed by the researchers administers ... effects completely automatically, with no manual intervention. , ...
Cached Medicine News:Health News:Professor Muhammad Yunus and The Green Children to Open First Grameen Eye Hospital in Bangladesh on May 12, 2008 2Health News:Professor Muhammad Yunus and The Green Children to Open First Grameen Eye Hospital in Bangladesh on May 12, 2008 3Health News:$45 billion a year is spent by public on health costs for full-time workers and families 2Health News:$45 billion a year is spent by public on health costs for full-time workers and families 3Health News:$45 billion a year is spent by public on health costs for full-time workers and families 4Health News:Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena 2Health News:Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena 3Health News:Protect Yourself From Teeth to Toes! Lindsay Price and Crest Whitestrips Daily Whitening + Tartar Protection Partner to Empower Women for the 9th Annual National Women's Health Week 2Health News:Protect Yourself From Teeth to Toes! Lindsay Price and Crest Whitestrips Daily Whitening + Tartar Protection Partner to Empower Women for the 9th Annual National Women's Health Week 3Health News:US Oncology Applauds Journal of Clinical Oncology Study Highlighting Value of PET Scans for Cancer Patients With Various Types of Malignancies 2Health News:US Oncology Applauds Journal of Clinical Oncology Study Highlighting Value of PET Scans for Cancer Patients With Various Types of Malignancies 3Health News:World first: researchers develop completely automated anesthesia system 2
... Thrombosis now has new ... transformation of complex algorithms ... images into dynamic step-by-step ... precise, up-to-date information for ...
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
... AHA Clinical Cardiac Consult is the ... guidance on the diagnosis and management ... abnormalities. From evaluation of chest pain ... congenital disease, this quick reference makes ...
Medicine Products: